Previous Close | 0.0050 |
Open | 0.0100 |
Bid | 0.0050 x N/A |
Ask | 0.0100 x N/A |
Day's Range | 0.0100 - 0.0100 |
52 Week Range | 0.0050 - 0.1000 |
Volume | |
Avg. Volume | 67,705 |
Market Cap | 2.637M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with relat
Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months ended June 30, 2023. Complete financial statements along with related ma
Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoYCompany completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as requiredToronto, Ontario--(Newsfile Corp. - July 31, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"),